Context Therapeutics Inc. (CNTX) Dividend History

Company News

• Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

  Context Therapeutics Inc. announced the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76, a Claudin 6 (CLDN6) x CD3 T cell engaging bispecific antibody, for CLDN6-positive gynecologic and testicular cancers. The company expects to share initial data in the first half of 2026.

  GlobeNewswire Inc.
• Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment

  The oncology field is advancing with emerging immunotherapies and AI-driven personalized cell therapies. Key players like Oncolytics Biotech, Erasca, Allogene Therapeutics, Context Therapeutics, and Recursion Pharmaceuticals are driving progress in areas like breast, GI, and renal cell cancers.

  Benzinga

  Featured Companies: ALLO ERAS ONCY RXRX
• Top 10 Small-Cap Stocks to Watch in 2025

  The article discusses 10 small-cap stocks that could outperform in 2025, citing factors like falling interest rates, low valuations, and potential shifts in industrial production.

  Investing.com

  Featured Companies: AUNA CRGO EVGO FFIC IKT IRD OKLO PENG WOLF
• Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year?

  Here is how CareCloud, Inc. (CCLD) and Context Therapeutics Inc. (CNTX) have performed compared to their sector so far this year.

  Zacks Investment Research

  Featured Companies: CCLD
• Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice

  Does Context Therapeutics Inc. (CNTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

  Zacks Investment Research